论文部分内容阅读
原发性肝癌(HCC)是临床上较为常见的恶性肿瘤,其发病率和死亡率一直都很高。美国癌症协会(ACS)发布的2007～2008年癌症统计分析报告显示,全球HCC发病率和死亡率在恶性肿瘤中分别排第6位和第3位,主要分布在中国和非洲等一些国家和地区[1]。目前HCC的治疗方法主要包括
Primary liver cancer (HCC) is a clinically common malignant tumor with high morbidity and mortality. According to the 2007-2008 Cancer Statistics Analysis Report released by the American Cancer Society (ACS), the incidence and mortality of HCC in the world ranked sixth and third respectively in malignant tumors, mainly in some countries and regions such as China and Africa [1]. The current treatment of HCC mainly include